Could I start with the first part of your question, which is, what are the precise instruments we're actually talking about?
What we've been proposing over the last years is an array of tools, and they include, for example, an ability to get companies to do studies, but others to do studies too. In terms of requiring changes on label, making sure that we have nice clear powers...and that's really the information about how to use the drug.
Reassessment. Reassessment is a really important component. In Europe, for example, they require reassessment every five years for every product. It's hard to know, after five years, what you now know about a drug right across the board. So what we're trying to do is study that tool, for example, and figure out how from a data point of view, how from a safety point of view, it is valuable to do a reassessment.
Those are the kinds of tools that we're studying, how they work in other jurisdictions, and then coming back and talking to Canadians—patient groups, academics, and others—about how those tools could work. So once they're hooked into the licensing situation, and you can make them obligations on market and then bring them back into our analysis, that's really where we have this conversation going on. So there are precise tools that you can lay in to do that.
I mentioned pharmacovigilance plans and risk management plans, which are commitments you make—